Q&A: AstraZeneca Execs Talk Immunotherapy Strategy And More At ASCO
Executive Summary
Chief Medical Officer Briggs Morrison and Senior VP for Oncology Global Portfolio and Product Strategy Mondher Mahjoubi sat down with “The Pink Sheet” to discuss the firm’s oncology strategy and outlook, including the choices it’s making with immuno-oncology, the valuation of the oncology franchise and the climate for cancer drug prices.
You may also be interested in...
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).
No More NASHing Of Teeth: Madrigal’s Resmetirom Approval Ends Years Of Industry Frustration
US FDA clears first MASH (formerly NASH) therapy, nearly four years after one had been initially anticipated. With the accelerated approval path established, Madrigal gets the opportunity to create a marketplace with Rezdiffra (resmetirom), and candidates in the pipeline get a clear target.
Publisher’s Spotlight: The Citeline Awards Are Open For Entries!
Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees.